Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.10    -0.05 (-4.55%)
Bid:
1.00
Ask:
1.10
Spread: 0.10 (10.00%)
Market Cap: £25.80m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

AJCN endorses Sirco

16 May 2006 07:01

Provexis PLC16 May 2006 PROVEXIS PLC ("Provexis" or the "Company") SircoTM science to be published in leading scientific journal Provexis, the nutraceutical company that develops scientifically-provenfunctional and medical foods, announces a major international scientificendorsement for its lead product SircoTM. Two scientific papers, which detailthe clinical efficacy of SircoTM, are to be published by the American Journal ofClinical Nutrition (AJCN). The AJCN is internationally recognised as thehighest-ranked peer-reviewed journal in the nutrition field. SircoTM, a chilled fruit juice, is the first heart health product to contain thepatented FruitflowTM technology. FruitflowTM is a natural bioactive extract fromtomato that works by reducing blood platelet aggregation within hours ofconsumption. Platelet aggregation plays a significant role in the formation of athrombus (internal blood clot) which can cause a heart attack or stroke. SircoTM is currently available in the UK in the chilled juice category in over550 Tesco and Waitrose stores. The product is targeted at adults who are keen tomaintain cardiovascular health. Commenting on the news of the acceptance by the journal, Dr Stephen Franklin,CEO of Provexis, said: "We are delighted that the science behind FruitflowTM has been accepted forpublication by the highest-ranked peer-reviewed scientific journal in the field.We have remained resolute in our belief that the FruitflowTM technology isworld-class and that this would be recognised by the most stringent scientificreview process in the field of clinical nutrition." "The acceptance of two separate scientific papers, published in thisinternationally accredited journal is a significant milestone for the Companyand an essential precursor to initiating a number of key commercial activities". For further information please contact: Provexis plcDr Stephen Franklin 020 8392 6631 Bell Pottinger Corporate & FinancialEmma Kent 020 7861 3232 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th May 20267:00 amRNSHolding(s) in Company
16th Apr 202612:37 pmRNSHolding(s) in Company
31st Dec 20258:22 amRNSHalf-year Financial Report
31st Dec 20258:22 amRNSHalf-year Financial Report
21st Nov 20251:38 pmRNSResult of AGM
30th Oct 20257:30 amRNSRestoration - Provexis plc
30th Oct 20257:00 amRNSFinal Results
1st Oct 20257:30 amRNSSuspension - Provexis PLC
30th Sep 20258:40 amRNSDelay in publication of annual accounts
7th Jan 20251:14 pmRNSGrant of Options and Warrants
31st Dec 20241:00 pmRNSTotal Voting Rights
31st Dec 20249:59 amRNSHalf-year Report
18th Dec 20247:00 amRNSPurchase of Fruitflow® II SD & royalty payment
25th Oct 20243:47 pmRNSResult of AGM
30th Sep 20247:00 amRNSFinal Results
30th Apr 20245:00 pmRNSTotal Voting Rights
28th Mar 20247:00 amRNSIssue of Equity - purchase of Fruitflow® II SD
29th Dec 202312:48 pmRNSHalf-year Report
26th Oct 20231:51 pmRNSResult of AGM
29th Sep 20237:00 amRNSFinal Results
30th Aug 20237:04 amRNSBYHEALTH regulatory filing with Chinese SAMR
3rd Apr 20237:00 amRNSCapital structure and funding update
24th Jan 202311:03 amRNSGrant of Share Options
30th Dec 20228:53 amRNSHalf-year Report
27th Oct 20221:12 pmRNSResult of AGM
14th Oct 20227:00 amRNSDirectorate Change
30th Sep 20227:00 amRNSFinal Results
22nd Jun 20227:00 amRNSTwo new agreements with DSM & patent application
31st May 20225:00 pmRNSTotal Voting Rights
17th May 202212:39 pmRNSExercise of Options and Total Voting Rights
31st Dec 20217:00 amRNSHalf-year Report
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
4th Nov 20211:30 pmRNSResult of AGM
4th Nov 202111:07 amRNSBy-Health Fruitflow agreement and support in R&D
1st Oct 20216:04 pmRNSGrant of Share Options
30th Sep 20217:00 amRNSFinal Results
9th Sep 20214:41 pmRNSSecond Price Monitoring Extn
9th Sep 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20214:35 pmRNSPrice Monitoring Extension
22nd Jul 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20214:35 pmRNSPrice Monitoring Extension
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
5th Jul 20214:35 pmRNSPrice Monitoring Extension
1st Jul 20214:40 pmRNSSecond Price Monitoring Extn
1st Jul 20214:35 pmRNSPrice Monitoring Extension
26th Feb 20215:00 pmRNSTotal Voting Rights
19th Feb 20217:30 amRNSDirector / PDMR notification
19th Feb 20217:00 amRNSPlacing of new ordinary shares to raise £50,000

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.